SCHEMBL10095348

SCHEMBL10095348

CCn1c(C#Cc2ccc(NS(=O)(=O)C(C)C)cc2)c(C#N)c2ccc(OC)cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
KDM4E B2RXH2 3/20 0.36
HTT P42858 3/20 0.36
LMNA P02545 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPK1 P28482 2/20 0.36
PABPC1 P11940 1/20 0.36
CASP3 P42574 1/20 0.36
NCOA1 Q15788 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
PGR P06401 5/20 0.35
DYRK1A Q13627 2/20 0.35
NR3C1 P04150 4/20 0.35
NR3C2 P08235 4/20 0.35
AR P10275 3/20 0.35
BRPF1 P55201 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10095407 0.90 ALDH1A1 (0.38) MAPTKDM4EHTTLMNAMEN1
SCHEMBL981984 0.90 PGR (0.43) MAPTKDM4EHTTLMNAMEN1
SCHEMBL981436 0.90 MAPT (0.38) MAPTKDM4EHTTLMNAMEN1
SCHEMBL10252473 0.87 DYRK1A (0.36) MAPTKDM4EHTTMEN1KMT2A
SCHEMBL10095291 0.84 L3MBTL1 (0.46) MAPTKDM4EHTTLMNAMEN1
SCHEMBL10095334 0.84 GRIK2 (0.43) MAPTKDM4EHTTLMNAMEN1
SCHEMBL982317 0.84 KDM4E (0.39) MAPTKDM4EHTTLMNAMEN1
SCHEMBL10095367 0.84 MAPT (0.43) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL982374 0.83 KDM4E (0.39) MAPTKDM4EHTTLMNAMEN1
SCHEMBL982903 0.82 PFKFB1 (0.44) MAPTKDM4EHTTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927576-B2 HCV inhibitor and therapeutic agent combinations PTC Therpeutics, Inc. (US) 2015-01-06 US disclosed
US-8927576-B2 HCV inhibitor and therapeutic agent combinations PTC Therpeutics, Inc. (US) 2015-01-06 US disclosed
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations PTC THERAPEUTICS, INC. (US) 2012-02-02 US disclosed
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
US-8013006-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-09-06 US disclosed
US-7868037-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-01-11 US disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 US disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus EIF2AK2, INMT, IDO1 MAPT 3963/4885KDM4E 433/4885HTT 1585/4885
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS MAPT 4416/4885KDM4E 3703/4885HTT 3355/4885
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations HAVCR2, SERPINB1, ENPEP MAPT 4044/4885KDM4E 4208/4885HTT 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.